newsfilter
← Latest News
PR Newswire·

Regen BioPharma, Inc. to Initiate Development of its Modified mRNA anti-Cancer Vaccine Technology

SAN DIEGO, Feb. 11, 2022 /PRNewswire/ -- Regen BioPharma, Inc. (OTC:RGBP) and (OTC:RGBPP) is embarking on a development program to commercialize its modified mRNA anti-cancer vaccine targeting the Survivin protein. In the first phase of the developmen